Morningstar Rating

Stock Research and Analysis

by Ben Johnson
DuPont is trying to rev its scientific engine and steer a course back toward its roots as a leading innovator. In certain areas -- like its agriculture and nutrition segment -- the firm has proven its creative ability, producing a steady stream of new   Read more 

Bulls Say

Its Pioneer plant genetics business gained share in the U.S. corn seed market for the first time in years in 2009.
DuPont's applied biosciences pipeline is full of projects with substantial long-term market potential, including second-generation biofuels and bio-based plastics. Read more 

Bears Say

The company expects pharmaceutical income to take its first major step down during 2010, when the U.S. exclusivity period for Cozaar ends. Pharmaceutical income has represented, on average, 22% of DuPont's segment-level pretax operating income over the past three years.
The delay of the introduction of the Optimum GAT trait in Pioneer's soybean and corn products is another black eye for a company that already has a mixed track record when it comes to trait integration. Read more 

Strategy

Innovation has once again taken center stage at DuPont. A steady pipeline of new products should bolster the firm's pricing power and provide room for margin expansion.  Read more 

Management

Ellen Kullman became CEO Jan. 1, 2009. She succeeded Charles Holliday, who had served as CEO since 1998. During her 20-year tenure with the firm, Kullman has proven to be a capable leader. From 2002 to 2006 she led the safety and protection segment,  Read more 

Profile

DuPont is a diversified chemical company. Its business is divided into five operating segments: agriculture and nutrition, coating and color technologies, electronic and   Read more 

First Name
Last Name
Email Address
Zip Code
Create Password
Verify Password
(6-15 characters; case sensitive)

Why Housing Could Come Back with a Vengeance 
Watch more 

View all of our analyst reports with a free trial to Morningstar.com Premium.